GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity.

Front Gastroenterol (Lausanne) · 2026 · PMC13222807 · PMID 42231903

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a smaller cohort of patients with more severe CD phenotypes, including 17% with perianal involvement and 24% with penetrating or fistulizing disease, numerical reductions across outcomes were observed in the GLP-1RA group, but these differences did not reach statistical significance ( 104 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.